Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Pediatric Ulcerative Colitis (ENVISION I)
NCT02065557Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in ulcerative colitis (UC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at 8 weeks and Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at 52 weeks. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02065557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065557.